| 03:34a | Australian Shares Rise to 10-Week High as Wage Growth Continues | MT |
| 02:58a | Australian shares rise after weak wage data, CSL caps gains | RE |
| 08/16 | CSL FY22 Profit Declines as Pandemic Constrains Core Plasma Therapy Sales; Shares Down .. | MT |
| 08/16 | Australia shares flat as miners offset CSL drag, NZ falls ahead of rates decision | RE |
| 08/16 | TRANSCRIPT : CSL Limited, 2022 Earnings Call, Aug 17, 2022 | CI |
| 08/16 | Australia biotech giant CSL reports profit dip, flags cost spiral | RE |
| 08/16 | CSL annual profit drops 6% as weak plasma collections bite | RE |
| 08/16 | CSL Limited Provides Earnings Guidance for the Fiscal Year 2023 | CI |
| 08/16 | CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 S.. | CI |
| 08/16 | CSL Limited Reports Earnings Results for the Full Year Ended June 30, 2022 | CI |
| 08/16 | CSL Net Profit Falls, But Expects Growth For Coming Year | DJ |
| 08/12 | WuXi Biologics Inc. Announces Change of Address of Principal Place of Business in Hong .. | CI |
| 08/10 | CSL Completes Vifor Pharma Acquisition | MT |
| 08/09 | UBS Starts Samsung Biologics at Buy With 1,070,000 Won Price Target | MT |
| 08/05 | Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy | MT |
| 08/05 | S.Korean shares post third straight weekly gain | RE |
| 08/01 | CSL Receives All Regulatory Approvals for Vifor Pharma Acquisition | MT |
| 08/01 | GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineeri.. | CI |
| 07/28 | Samsung Biologics' Net Income Jumps 25.1% in June Quarter | MT |
| 07/26 | Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi.. | MT |
| 07/26 | Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi.. | MT |
| 07/26 | U.S. FDA accepts Biogen's ALS therapy for review | RE |
| 07/26 | U.S. FDA grants priority review to Biogen's ALS drug | RE |
| 07/26 | Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review o.. | CI |
| 07/26 | Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS | DJ |
| 07/22 | China’s Wuxi AppTec, Wuxi Biologics to Each Invest $1.4 Billion in Singapore | MT |
| 07/21 | JPMorgan Raises Biogen's Price Target to $221 From $219, Neutral Rating Maintained | MT |
| 07/21 | Goldman Sachs Raises Biogen's Price Target to $220 From $213, Maintains Neutral Rating | MT |
| 07/21 | UBS Adjusts Biogen Price Target to $238 From $247, Maintains Buy Rating | MT |
| 07/21 | Cowen Adjusts Biogen's Price Target to $270 From $285; Outperform Rating Kept | MT |
| 07/21 | Truist Securities Adjusts Biogen's Price Target to $270 From $320, Reiterates Buy Ratin.. | MT |
| 07/21 | Needham Adjusts Biogen's Price Target to $250 From $262, Reiterates Buy Rating | MT |
| 07/21 | Barclays Lowers Biogen's Price Target to $200 From $210, Maintains Equalweight Rating | MT |
| 07/21 | RBC Cuts Price Target on Biogen to $259 From $264, Maintains Outperform Rating | MT |
| 07/21 | ANALYST RECOMMENDATIONS : Tesla, Nike, Netflix, Idexx Laboratories, Biogen... | |
| 07/21 | Wedbush Cuts Biogen's Price Target to $183 From $188 Amid 'Revenue Erosion;' Neutral Ra.. | MT |
| 07/20 | US Stocks Close Higher Wednesday, Led by Consumer Discretionary, Tech | MT |
| 07/20 | US Stocks Close Higher Wednesday Despite Steeper-Than-Expected Existing-Home Sales Decl.. | MT |
| 07/20 | Biogen Faces Declining Sequential Revenue Despite Positive Q2 Results, Wedbush Says | MT |
| 07/20 | Biogen Shares Decline After Company Reports Lower Q2 Profits, Revenue | MT |
| 07/20 | TRANSCRIPT : Biogen Inc., Q2 2022 Earnings Call, Jul 20, 2022 | CI |
| 07/20 | Biogen Reports Lower Q2 Profits, Revenue | MT |
| 07/20 | Biogen leans on new Alzheimer's drug to calm investor worries | RE |
| 07/20 | Biogen profit more than doubles on Samsung Bioepis stake sale | RE |
| 07/20 | Biogen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 3.. | CI |
| 07/20 | Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020. | CI |
| 07/20 | Biogen Inc. Updates Earnings Guidance for Full Year 2022 | CI |
| 07/19 | Samsung Biologics to Add a Second Manufacturing Campus Near Seoul | MT |
| 07/19 | WuXi Biologics Sees Up to 38% Jump in H1 Profit | MT |
| 07/18 | WuXi Biologics Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022 | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
